Journal article Open Access

Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β signaling

Hartwig, Kerstin; Fackler, Viktoria; Jaksch-Bogensperger, Heidi; Furtner, Tanja; Couillard-Despres, Sébastien; Meier, Dieter; Moessler, Herbert; Winter, Stefan; Aigner, Ludwig


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="a">2016-02-02</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">neuroprotection</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">neurotrophic factotrs</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">cell death</subfield>
  </datafield>
  <controlfield tag="005">20200120173524.0</controlfield>
  <controlfield tag="001">16487</controlfield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">EVER Neuro Pharma, Unterach, Austria</subfield>
    <subfield code="a">Fackler, Viktoria</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria</subfield>
    <subfield code="a">Jaksch-Bogensperger, Heidi</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria</subfield>
    <subfield code="a">Furtner, Tanja</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria and Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria and Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria</subfield>
    <subfield code="a">Couillard-Despres, Sébastien</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">EVER Neuro Pharma, Unterach, Austria</subfield>
    <subfield code="a">Meier, Dieter</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">EVER Neuro Pharma, Unterach, Austria</subfield>
    <subfield code="a">Moessler, Herbert</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">EVER Neuro Pharma, Unterach, Austria</subfield>
    <subfield code="a">Winter, Stefan</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria and Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria</subfield>
    <subfield code="a">Aigner, Ludwig</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">872213</subfield>
    <subfield code="z">md5:a93c97a8a92482c0385e147d5c19c2ca</subfield>
    <subfield code="u">https://zenodo.org/record/16487/files/Hartwig_IntJDevNeurosci_2014-P03-AAM.pdf</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2014-08-02</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="p">user-ecfunded</subfield>
    <subfield code="p">user-inmind</subfield>
    <subfield code="o">oai:zenodo.org:16487</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="c">52-8</subfield>
    <subfield code="p">Int J Dev Neurosci. </subfield>
    <subfield code="v">38</subfield>
    <subfield code="y">2014</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">EVER Neuro Pharma, Unterach, Austria</subfield>
    <subfield code="a">Hartwig, Kerstin</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β signaling</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-inmind</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-ecfunded</subfield>
  </datafield>
  <datafield tag="536" ind1=" " ind2=" ">
    <subfield code="c">278850</subfield>
    <subfield code="a">Imaging of Neuroinflammation in Neurodegenerative Diseases</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">http://creativecommons.org/licenses/by/4.0/legalcode</subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;Cerebrolysin (EVER Neuro Pharma, Austria) is a peptidergic drug indicated for clinical use in stroke, traumatic brain injury and dementias. The therapeutic effect of Cerebrolysin is thought to ensure from its neurotrophic activity, which shares some properties with naturally occurring neurotrophic factors. However, the exact mechanism(s) of action of Cerebrolysin is yet to be fully deciphered. This study aimed to investigate the neuroprotective effect of Cerebrolysin in a widely used in vitro model of hypoxia-induced neuronal cytotoxicity, namely CoCl2-treatment of PC12 cells. CoCl2 cytotoxicity was indicated by a reduced cell-diameter, cell shrinkage, increased pro-apoptotic caspase-activities and a decreased metabolic activity. Cerebrolysin maintained the cell-diameter of CoCl2-treated na&amp;iuml;ve PC12 cells, decreased the activation of caspase 3/7 in na&amp;iuml;ve PC12 cells and restored the cells&amp;rsquo; metabolic activity in na&amp;iuml;ve and differentiated PC12 cells. Cerebrolysin treatment also decreased the levels of superoxides observed after exposure to CoCl2. Investigating the mechanism of action, we could demonstrate that Cerebrolysin application to CoCl2-stressed PC12 cells increased the phosphorylation of GSK3&amp;szlig;, resulting in the inhibition of GSK3&amp;szlig;. This might become clinically relevant for Alzheimer&amp;rsquo;s disease, since GSK3&amp;szlig; activity has been linked to the production of amyloid beta. Taken together, Cerebrolysin was found to have neuroprotective effects in CoCl2-induced cytotoxicity in PC12 cells.&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1016/j.ijdevneu.2014.07.00</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
</record>
86
197
views
downloads
Views 86
Downloads 197
Data volume 171.8 MB
Unique views 80
Unique downloads 196

Share

Cite as